

Heart Failure – Part 2

According to 2021 ESC guidelines



Jacek Kubica Collegium Medicum Nicolaus Copernicus University





Therapeutic algorithm of Class I Therapy Indications for a patient with heart failure with reduced ejection fraction

ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptor-neprilysin inhibitor; CRT-D = cardiac resynchronization therapy with defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; ICD = implantable cardioverter-defibrillator; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; QRS = Q, R, and S waves of an ECG; SR = sinus rhythm. ^aAs a replacement for ACE-I. ^bWhere appropriate. Class I=green. Class IIa=Yellow.

Pharmacological treatments indicated in patients with (NYHA class II-IV) ESC heart failure with reduced ejection fraction (LVEF ≤40%) **Class Level Recommendations** An ACE-I is recommended for patients with HFrEF to reduce the risk of HF Α hospitalization and death. A beta-blocker is recommended for patients with stable HFrEF to reduce the risk Α of HF hospitalization and death. An MRA is recommended for patients with HFrEF to reduce the risk of HF Α hospitalization and death. Dapagliflozin or empagliflozin are recommended for patients with HFrEF to Α reduce the risk of HF hospitalization and death. Sacubitril/valsartan is recommended as a replacement for an ACE-I in patients R with HFrEF to reduce the risk of HF hospitalization and death. ACE-I = angiotensin-converting enzyme inhibitor; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction;

MRA = mineralocorticoid receptor antagonist; NYHA= New York Heart Association.

Other pharmacological treatments indicated in selected patients with WESC NYHA class II-IV heart failure with reduced ejection fraction (LVEF ≤40%) (1)

Recommendations	Class	Level
Loop diuretics		
Diuretics are recommended in patients with HFrEF with signs and/or symptoms of		
congestion to alleviate HF symptoms, improve exercise	1 I -	С
capacity, and reduce HF hospitalizations.		
ARB		
An ARB ^a is recommended to reduce the risk of HF hospitalization and		
CV death in symptomatic patients unable to tolerate an ACE-I or ARNI	- I	В
(patients should also receive a beta-blocker and an MRA).		
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; CV = cardiovascular; HF = heart Ference and the second election fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association.	art failure;	

^aThe ARBs with evidence in HFrEF are candesartan, losartan, and valsartan.

Other pharmacological treatments indicated in selected patients with WESC NYHA class II-IV heart failure with reduced ejection fraction (LVEF ≤40%) (2)

RecommendationsClassLevelI_f-channel inhibitorIvabradine should be considered in symptomatic patients with LVEF ≤35%, in SR and a
resting heart rate ≥70 b.p.m. despite treatment with an evidence-based dose of beta-
blocker (or maximum tolerated dose below that), ACE-I/(or ARNI), and an MRA, to
reduce the risk of HF hospitalization and CV death.IIaBIvabradine should be considered in symptomatic patients with LVEF ≤35%, in SR and a
resting heart rate ≥70 b.p.m. who are unable to tolerate or have contraindications for a
beta-blocker to reduce the risk of HF hospitalization and CV death. Patients should also
receive an ACE-I (or ARNI) and an MRA.IIaC

ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptor-neprilysin inhibitor; b.p.m. = beats per minute; CV = cardiovascular; HF = heart failure; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA= New York Heart Association; SR = sinus rhythm.

Other pharmacological treatments indicated in selected patients with NYHA class II-IV heart failure with reduced ejection fraction (LVEF ≤40%) (3)

Recommendations

Class Level

IIb

lla

llb

B

B

B

Soluble guanylate cyclase stimulator

Vericiguat may be considered in patients in NYHA class II-IV who have had worsening HF despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of CV mortality or HF hospitalization.

Hydralazine and isosorbide dinitrate

Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with LVEF ≤35% or with an LVEF <45% combined with a dilated left ventricle in NYHA class III-IV despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of HF hospitalization and death.

Hydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF who cannot tolerate any of an ACE-I, an ARB, or ARNI (or they are contraindicated) to reduce the risk of death.

ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptor-neprilysin inhibitor; CV = cardiovascular; HF = heart failure; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA= New York Heart Association.

Other pharmacological treatments indicated in selected patients with NYHA class II-IV heart failure with reduced ejection fraction (LVEF ≤40%) (4)

Recommendations

Class Level

B


llb

Digoxin

Digoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA, to reduce the risk of hospitalization (both all-cause and HF hospitalizations).

ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptor-neprilysin inhibitor; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist.

ESC



Strategic phenotypic overview of the management of heart failure with reduced ejection fraction

ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; BB = beta-blocker; b.p.m. = beats per minute; BTC = bridge to candidacy; BTT = bridge to transplantation; CABG = coronary artery bypass graft; CRT-D = cardiac resynchronization therapy with defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; DT = destination therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-defibrillator; ISDN = isosorbide dinitrate; LBBB = left bundle branch block; MCS = mechanical circulatory support; MRA = mineralocorticoid receptor antagonist; MV = mitral valve; PVI = pulmonary vein isolation; QOL = quality of life; SAVR = surgical aortic valve replacement; SGLT2i = sodium-glucose co-transporter 2 inhibitor; SR = sinus rhythm; TAVI = transcatheter aortic valve replacement; TEE = transcatheter edge to edge. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa (see Table 1 for further details on classes of recommendation). The Figure showsmanagement options with Class I and IIa recommendations. See the specific Tables for those with Class IIb recommendations.

ESC

www.escardio.org/guidelines

Recommendations	Class	Leve
Secondary prevention		
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing naemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of reversible causes or unless the ventricular arrhythmia has occurred <48 h after a MI.	•	A
Primary prevention		
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II-III) of an ischaemic aetiology (unless they have had a MI in the prior 40 days—see below), and an LVEF ≤35% despite ≥3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status.	I	Α


HF = heart failure; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NYHA = New York Heart Association; OMT= optimal medical therapy.

Recommendations for an implantable cardioverter-defibrillator in patients with heart failure (2) **Recommendations Class Level Primary prevention (continued)** An ICD should be considered to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II-III) of a non-ischaemic lla Α aetiology, and an LVEF \leq 35% despite \geq 3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status. Patients should be carefully evaluated by an experienced cardiologist before generator replacement, because management goals, the patient's needs and lla R clinical status may have changed. A wearable ICD may be considered for patients with HF who are at risk of sudden llb B cardiac death for a limited period or as a bridge to an implanted device.

HF = heart failure; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OMT= optimal medical therapy.



Recommendations for an implantable cardioverter-defibrillator in patients with heart failure (3)



CRT = cardiac resynchronization therapy; ICD = implantable cardioverter-defibrillator; NYHA = New York Heart Association; VAD = ventricular assist device.



Recommendations for cardiac resynchronization therapy implantation in **WESC** patients with heart failure (1)

Recommendations	Class	Level
CRT is recommended for symptomatic patients with HF in SR with a QRS duration \geq 150 ms and LBBB QRS morphology and with LVEF \leq 35% despite OMT in order to improve symptoms and reduce morbidity and mortality.		Α
CRT should be considered for symptomatic patients with HF in SR with a QRS duration of 130–149 ms and LBBB QRS morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality.		В
CRT should be considered for symptomatic patients with HF in SR with a QRS duration \geq 150 ms and non-LBBB QRS morphology and with LVEF \leq 35% despite OMT in order to improve symptoms and reduce morbidity and mortality.		В
CRT may be considered for symptomatic patients with HF in SR with a QRS duration of 130–149 ms and non-LBBB QRS morphology and with LVEF ≤35% despite OMT in order to improve symptoms and reduce morbidity and mortality.		В

AF = atrial fibrillation; AV = atrio-ventricular; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-defibrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; NYHA= New York Heart Association; OMT= optimal medical therapy (class I recommended medical therapies for at least 3 months); QRS =Q, R, and S waves of an ECG; RV = right ventricular; SR = sinus rhythm.

Recommendations for cardiac resynchronization therapy implantation in **ESC** patients with heart failure (2)

Recommendations	Class	Level
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high degree AV block in order to reduce morbidity. This includes patients with AF.	I.	Α
Patients with an LVEF ≤35% who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a significant proportion of RV pacing should be considered for 'upgrade' to CRT.	lla	В
CRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high degree AV block.	- M	Α

AF = atrial fibrillation; AV = atrio-ventricular; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-defibrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; NYHA= New York Heart Association; OMT= optimal medical therapy (class I recommended medical therapies for at least 3 months); QRS = Q, R, and S waves of an ECG; RV = right ventricular; SR = sinus rhythm.

Pharmacological treatments to be considered in patients with (NYHA class II-IV) heart failure with mildly reduced ejection fraction



		•		
Recommendations			Class	Level
Diuretics are recommended in patients with cor alleviate symptoms and signs.	gestion and HF	mrEF in order to	Т	С
An ACE-I may be considered for patients with HI hospitalization and death.	[:] mrEF to reduce	e the risk of HF	IIb	С
An ARB may be considered for patients with HFr hospitalization and death.	nrEF to reduce	the risk of HF	IIb	С
A beta-blocker may be considered for patients w HF hospitalization and death.	/ith HFmrEF to r	reduce the risk of	IIb	С
An MRA may be considered for patients with HF hospitalization and death.	mrEF to reduce	the risk of HF	IIb	С
Sacubitril/valsartan may be considered for patie risk of HF hospitalization and death.	nts with HFmrE	F to reduce the	llb	С

ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA= New York Heart Association.

Screening for, and treatment of, aetiologies, and cardiovascular and noncardiovascular comorbidities is recommended in patients with HFpEF (see relevant sections of this document).

Diuretics are recommended in congested patients with HFpEF in order to alleviate symptoms and signs.

Recommendations for the treatment of patients with heart failure with

HFpEF = heart failure with preserved ejection fraction.

Recommendations

preserved ejection fraction



Class Level

Recommendations for the primary prevention of heart failure in patients **W**ESC with risk factors for its development

Recommendations	Class	Level
Treatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent HF hospitalizations.	I	Α
Treatment with statins is recommended in patients at high risk of CV disease or with CV disease in order to prevent or delay the onset of HF, and to prevent HF hospitalizations.	I	Α
SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin) are recommended in patients with diabetes at high risk of CV disease or with CV disease in order to prevent HF hospitalizations.	I	Α
Counselling against sedentary habit, obesity, cigarette smoking, and alcohol abuse is recommended to prevent or delay the onset of HF.	I.	С

CV=cardiovascular; HF=heart failure; SGLT2=sodium-glucose co-transporter 2.

Recommendations for the treatment of patients with advanced heart failure (1)

Recommendations	Class	Level
Patients being considered for long-term MCS must have good compliance, appropriate capacity for device handling and psychosocial support.	1	С
Heart transplantation is recommended for patients with advanced HF, refractory to medical/ device therapy and who do not have absolute contraindications.	1	С
Long-term MCS should be considered in patients with advanced HFrEF despite optimal medical and device therapy, not eligible for heart transplantation or other surgical options, and without severe right ventricular dysfunction, to reduce the risk of death and improve symptoms.	lla	Α
Long-term MCS should be considered in patients with advanced HFrEF refractory to optimal medical and device therapy as a bridge to cardiac transplantation in order to improve symptoms, reduce the risk of HF hospitalization and the risk of premature death.	lla	В

HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MCS = mechanical circulatory support.

ESC

©ESC

Recommendations for the treatment of patients with advanced heart failure (2)

Recommendations	Class	Level
Renal replacement therapy should be considered in patients with refractory volume overload and end-stage kidney failure	lla	С
Continuous inotropes and/or vasopressors may be considered in patients with low cardiac output and evidence of organ hypoperfusion as bridge to MCS or heart transplantation.	llb	С
Ultrafiltration may be considered in refractory volume overload unresponsive to diuretic treatment.	llb	С
MCS = mechanical circulatory support.		

ESC